Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Hongkong, Italy, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.85
AMGN's Cash-to-Debt is ranked lower than
82% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. AMGN: 0.85 )
Ranked among companies with meaningful Cash-to-Debt only.
AMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.98 Max: 8.25
Current: 0.85
0.17
8.25
Equity-to-Asset 0.22
AMGN's Equity-to-Asset is ranked lower than
87% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AMGN: 0.22 )
Ranked among companies with meaningful Equity-to-Asset only.
AMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.62 Max: 0.84
Current: 0.22
0.22
0.84
Debt-to-Equity 2.31
AMGN's Debt-to-Equity is ranked lower than
94% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. AMGN: 2.31 )
Ranked among companies with meaningful Debt-to-Equity only.
AMGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.24 Max: 2.31
Current: 2.31
0.03
2.31
Debt-to-EBITDA 2.64
AMGN's Debt-to-EBITDA is ranked lower than
62% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. AMGN: 2.64 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.53  Med: 2.79 Max: 4.24
Current: 2.64
1.53
4.24
Interest Coverage 7.63
AMGN's Interest Coverage is ranked lower than
88% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMGN: 7.63 )
Ranked among companies with meaningful Interest Coverage only.
AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 5.3  Med: 7.7 Max: 9.53
Current: 7.63
5.3
9.53
Piotroski F-Score: 6
Altman Z-Score: 2.50
Beneish M-Score: -3.12
WACC vs ROIC
10.63%
10.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 44.17
AMGN's Operating Margin % is ranked higher than
96% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. AMGN: 44.17 )
Ranked among companies with meaningful Operating Margin % only.
AMGN' s Operating Margin % Range Over the Past 10 Years
Min: 27.67  Med: 35.8 Max: 44.17
Current: 44.17
27.67
44.17
Net Margin % 10.19
AMGN's Net Margin % is ranked higher than
83% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. AMGN: 10.19 )
Ranked among companies with meaningful Net Margin % only.
AMGN' s Net Margin % Range Over the Past 10 Years
Min: 8.66  Med: 27.11 Max: 33.59
Current: 10.19
8.66
33.59
ROE % 9.87
AMGN's ROE % is ranked higher than
87% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. AMGN: 9.87 )
Ranked among companies with meaningful ROE % only.
AMGN' s ROE % Range Over the Past 10 Years
Min: 7.18  Med: 21.47 Max: 26.65
Current: 9.87
7.18
26.65
ROA % 3.12
AMGN's ROA % is ranked higher than
83% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. AMGN: 3.12 )
Ranked among companies with meaningful ROA % only.
AMGN' s ROA % Range Over the Past 10 Years
Min: 2.51  Med: 9.16 Max: 12.11
Current: 3.12
2.51
12.11
ROC (Joel Greenblatt) % 176.74
AMGN's ROC (Joel Greenblatt) % is ranked higher than
96% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. AMGN: 176.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 68.74  Med: 87.88 Max: 196.88
Current: 176.74
68.74
196.88
3-Year Revenue Growth Rate 6.10
AMGN's 3-Year Revenue Growth Rate is ranked higher than
58% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMGN: 6.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.8  Med: 15.2 Max: 121.7
Current: 6.1
5.8
121.7
3-Year EBITDA Growth Rate 15.50
AMGN's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. AMGN: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.1 Max: 386.6
Current: 15.5
0
386.6
3-Year EPS without NRI Growth Rate -26.20
AMGN's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. AMGN: -26.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.2 Max: 124.6
Current: -26.2
0
124.6
GuruFocus has detected 3 Warning Signs with Amgen Inc AMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMGN's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

AMGN Guru Trades in Q3 2017

Pioneer Investments 288,126 sh (+223.10%)
Ray Dalio 59,273 sh (+124.38%)
Barrow, Hanley, Mewhinney & Strauss 307 sh (+24.29%)
Jim Simons 3,917,700 sh (+15.22%)
Ken Fisher 129,392 sh (+2.26%)
Joel Greenblatt 237,851 sh (+1.52%)
John Buckingham 57,579 sh (+0.88%)
Richard Snow 51,727 sh (+0.20%)
David Carlson 440,000 sh (unchged)
Jeff Auxier 3,300 sh (unchged)
Jeremy Grantham 2,200 sh (unchged)
David Dreman 6,049 sh (unchged)
Martin Whitman 176,500 sh (unchged)
Lee Ainslie Sold Out
Caxton Associates Sold Out
Third Avenue Management 210,124 sh (-0.15%)
Manning & Napier Advisors, Inc 114,745 sh (-0.37%)
PRIMECAP Management 22,259,358 sh (-3.15%)
Richard Pzena 1,255 sh (-6.27%)
Mairs and Power 8,129 sh (-6.39%)
Dodge & Cox 27,837 sh (-10.60%)
Charles Brandes 29,224 sh (-36.10%)
Mario Gabelli 11,332 sh (-45.95%)
First Eagle Investment 121,835 sh (-70.48%)
» More
Q4 2017

AMGN Guru Trades in Q4 2017

Caxton Associates 6,854 sh (New)
Paul Tudor Jones 9,716 sh (New)
Pioneer Investments 1,389,775 sh (+382.35%)
Barrow, Hanley, Mewhinney & Strauss 647 sh (+110.75%)
Richard Pzena 1,688 sh (+34.50%)
Jim Simons 4,579,445 sh (+16.89%)
Third Avenue Management 216,733 sh (+3.15%)
Richard Snow 52,381 sh (+1.26%)
Jeff Auxier 3,340 sh (+1.21%)
David Carlson 440,000 sh (unchged)
David Dreman 6,049 sh (unchged)
Martin Whitman 176,500 sh (unchged)
First Eagle Investment Sold Out
John Buckingham 57,459 sh (-0.21%)
PRIMECAP Management 22,030,249 sh (-1.03%)
Mairs and Power 7,963 sh (-2.04%)
Dodge & Cox 26,697 sh (-4.10%)
Charles Brandes 27,438 sh (-6.11%)
Jeremy Grantham 2,000 sh (-9.09%)
Joel Greenblatt 213,658 sh (-10.17%)
Ken Fisher 112,087 sh (-13.37%)
Mario Gabelli 5,341 sh (-52.87%)
Ray Dalio 15,987 sh (-73.03%)
» More
Q1 2018

AMGN Guru Trades in Q1 2018

Richard Pzena 1,341,311 sh (+79361.55%)
Ray Dalio 62,499 sh (+290.94%)
Jeremy Grantham 6,900 sh (+245.00%)
Paul Tudor Jones 25,254 sh (+159.92%)
Barrow, Hanley, Mewhinney & Strauss 1,236 sh (+91.04%)
Jeff Auxier 5,058 sh (+51.44%)
Ken Fisher 146,064 sh (+30.31%)
Joel Greenblatt 273,355 sh (+27.94%)
Mairs and Power 9,948 sh (+24.93%)
Mario Gabelli 5,406 sh (+1.22%)
Martin Whitman 176,500 sh (unchged)
Third Avenue Management Sold Out
John Buckingham 56,892 sh (-0.99%)
Pioneer Investments 1,361,654 sh (-2.02%)
PRIMECAP Management 21,442,344 sh (-2.67%)
Charles Brandes 25,857 sh (-5.76%)
Dodge & Cox 24,772 sh (-7.21%)
Jim Simons 3,925,300 sh (-14.28%)
Richard Snow 33,773 sh (-35.52%)
David Carlson 215,000 sh (-51.14%)
Caxton Associates 2,841 sh (-58.55%)
David Dreman 230 sh (-96.20%)
» More
Q2 2018

AMGN Guru Trades in Q2 2018

Jeremy Grantham 9,300 sh (+34.78%)
Jeff Auxier 6,128 sh (+21.15%)
Richard Pzena 1,578,099 sh (+17.65%)
Pioneer Investments 1,428,292 sh (+4.89%)
Mairs and Power 10,219 sh (+2.72%)
Ken Fisher 149,006 sh (+2.01%)
David Carlson Sold Out
Ray Dalio Sold Out
Caxton Associates Sold Out
Martin Whitman Sold Out
John Buckingham 56,224 sh (-1.17%)
PRIMECAP Management 21,173,744 sh (-1.25%)
Dodge & Cox 24,322 sh (-1.82%)
Mario Gabelli 5,261 sh (-2.68%)
Charles Brandes 25,118 sh (-2.86%)
Richard Snow 32,735 sh (-3.07%)
Jim Simons 3,803,600 sh (-3.10%)
Barrow, Hanley, Mewhinney & Strauss 1,043 sh (-15.61%)
Paul Tudor Jones 16,497 sh (-34.68%)
Joel Greenblatt 154,508 sh (-43.48%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Pzena 2018-06-30 Add 17.65%0.22%$166.05 - $186.51 $ 197.4212%1,578,099
Joel Greenblatt 2018-06-30 Reduce -43.48%0.28%$166.05 - $186.51 $ 197.4212%154,508
Ken Fisher 2018-06-30 Add 2.01%$166.05 - $186.51 $ 197.4212%149,006
Charles Brandes 2018-06-30 Reduce -2.86%$166.05 - $186.51 $ 197.4212%25,118
Dodge & Cox 2018-06-30 Reduce -1.82%$166.05 - $186.51 $ 197.4212%24,322
Mario Gabelli 2018-06-30 Reduce -2.68%$166.05 - $186.51 $ 197.4212%5,261
Barrow, Hanley, Mewhinney & Strauss 2018-06-30 Reduce -15.61%$166.05 - $186.51 $ 197.4212%1,043
Martin Whitman 2018-04-30 Sold Out 3.35%$166.05 - $191.1 $ 197.4210%0
Richard Pzena 2018-03-31 Add 79361.55%1.16%$169.43 - $198 $ 197.428%1,341,311
Joel Greenblatt 2018-03-31 Add 27.94%0.14%$169.43 - $198 $ 197.428%273,355
Ken Fisher 2018-03-31 Add 30.31%0.01%$169.43 - $198 $ 197.428%146,064
Charles Brandes 2018-03-31 Reduce -5.76%0.01%$169.43 - $198 $ 197.428%25,857
Dodge & Cox 2018-03-31 Reduce -7.21%$169.43 - $198 $ 197.428%24,772
Mario Gabelli 2018-03-31 Add 1.22%$169.43 - $198 $ 197.428%5,406
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Add 91.04%$169.43 - $198 $ 197.428%1,236
David Dreman 2018-03-31 Reduce -96.20%0.57%$169.43 - $198 $ 197.428%230
Third Avenue Management 2018-03-31 Sold Out 1.81%$169.43 - $198 $ 197.428%0
Third Avenue Management 2017-12-31 Add 3.15%0.06%$168.79 - $188.59 $ 197.4212%216,733
Joel Greenblatt 2017-12-31 Reduce -10.17%0.07%$168.79 - $188.59 $ 197.4212%213,658
Ken Fisher 2017-12-31 Reduce -13.37%0.01%$168.79 - $188.59 $ 197.4212%112,087
Charles Brandes 2017-12-31 Reduce -6.11%0.01%$168.79 - $188.59 $ 197.4212%27,438
Dodge & Cox 2017-12-31 Reduce -4.10%$168.79 - $188.59 $ 197.4212%26,697
Mario Gabelli 2017-12-31 Reduce -52.87%0.01%$168.79 - $188.59 $ 197.4212%5,341
Richard Pzena 2017-12-31 Add 34.50%$168.79 - $188.59 $ 197.4212%1,688
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Add 110.75%$168.79 - $188.59 $ 197.4212%647
First Eagle Investment 2017-12-31 Sold Out 0.05%$168.79 - $188.59 $ 197.4212%0
Joel Greenblatt 2017-09-30 Add 1.52%0.01%$167.29 - $191 $ 197.4211%237,851
Third Avenue Management 2017-09-30 Reduce -0.15%$167.29 - $191 $ 197.4211%210,124
Ken Fisher 2017-09-30 Add 2.26%$167.29 - $191 $ 197.4211%129,392
First Eagle Investment 2017-09-30 Reduce -70.48%0.12%$167.29 - $191 $ 197.4211%121,835
Charles Brandes 2017-09-30 Reduce -36.10%0.04%$167.29 - $191 $ 197.4211%29,224
Dodge & Cox 2017-09-30 Reduce -10.60%$167.29 - $191 $ 197.4211%27,837
Mario Gabelli 2017-09-30 Reduce -45.95%0.01%$167.29 - $191 $ 197.4211%11,332
Richard Pzena 2017-09-30 Reduce -6.27%$167.29 - $191 $ 197.4211%1,255
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Add 24.29%$167.29 - $191 $ 197.4211%307
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OCSE:NOVO B, NAS:GILD, NAS:CELG, ASX:CSL, NAS:BIIB, LSE:SHP, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:AMGN.Argentina, AMGN.Austria, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMGN.Italy, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Headquarter Location:USA
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.

Amgen Inc is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix and received approval for bone-strengthening drug Prolia/Xgeva.

Guru Investment Theses on Amgen Inc

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Livallova

Investor neglect can be a source of new ideas while also providing an element of downside protection. We found this combination to be compelling in our purchase of Livallova (NASDAQ:LIVN), which is the new name for Sorin and Cyberonics post their late-2015 merger. We think investor neglect was paramount, for Sorin, an Italian company, which merged with Cyberonics, based in Houston, changed its name and reincorporated in London. Indeed, we came across the company on a screen of our potential universe of companies, and had to do some digging into the new name we did not recognize, to realize the potential for these two well-known companies and the significant potential their merger offers.

Livallova is a healthcare company with a $3 billion market capitalization that holds leading positions in cardiac surgical equipment, surgical heart valve replacement, neuromodulation and cardiac rhythm management. In its cardiac surgery division, Livallova holds number one positions in Oxygenators and Heart Lung machines. It also is rapidly gaining share with its new sutureless Perceval heart valve, with a history of successful procedures in Europe and recently approved in the U.S. In Neuromodulation, Livallova holds the number one position in devices for the treatment of drug resistant epilepsy, led by its success with its AspireSR device. Livallova is also rapidly gaining share in cardiac rhythm management with Kora250 and Platinium in Japan and Europe, while retaining options on strategies to re-enter the U.S. market. In all, Livallova holds number one positions in over 60% of its revenues.

Livallova also has a strong self-help profile, with targeted synergies from its merger of $80 million over three years. As of its second quarter earnings call, Livallova indicated it was ahead of the first phase of $19 million expected in 2016. Creditworthiness for the company is easily demonstrated by net debt of roughly $75 million.

The ability to compound earnings and book value growth is not only supported by its new product introductions and merger synergies, but also its compelling research and development pipeline, which Livallova refers to as its New Ventures unit. In this unit, Livallova is pursuing groundbreaking new technologies in percutaneous mitral valve repair and replacement, the adaption of its Neuromodulation technologies for treatment of central and obstructive sleep apnea and also the potential to treat heart failure through vagus nerve stimulation. Not only is the potential market opportunity for all three of these areas separately in excess of a billion dollars, but through its merger, Livallova has multiple research efforts in each area to evaluate, streamline and prioritize.

Brexit created a window to initiate a position at under $50 per share for the Fund, which represents a compelling 50% upside to our fair value NAV target. Perhaps due to investor neglect on the name, Livallova trades at a substantial discount to its U.S. peers. We think this discount and its relatively smaller market capitalization also provide downside protection, for the company would likely be attractive to a larger entity looking to expand its product franchise.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Amgen (NASDAQ:AMGN), which was founded in 1980, is one of the world's leading biotechnology companies. Interestingly, the biotech industry has matured over the years and some of the companies generate stable cash flows, not unlike some of the larger pharmaceutical companies. Amgen is one of these. Competitive issues, largely surrounding the biosimilar debate, have put pressure on Amgen's stock. Post-Brexit market volatility provided us an opportunity to acquire shares.

Amgen has a diversified product portfolio across six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its key products are Enbrel for long-term inflammatory diseases such as rheumatoid arthritis; Epogen and Aranesp for anemia; Neupogen and Neulasta for treating neutropenia (a lack of certain white blood cells caused by cancer, bone marrow transplant, or after chemotherapy). Newer drugs include Repatha, which targets high cholesterol for the roughly 20% of the population who are intolerant of statins (the typical first line treatment), and Kyprolis for multiple myeloma, an incurable bone cancer. Its pipeline consists of 31

preclinical and clinical targets, 12 of which are in the later stages. Amgen also has a pipeline of 9 biosimilars, of which 3 are in late stage and for which the worldwide sales of the originator drugs totaled approximately $54 billion in 2015.

The company generated $9 billion in operating cash flow in 2015, up from $5.1 billion in 2011. The company has used its excess cash flow to fund growth as well as return cash to shareholders via both share buybacks and dividends. It expects to return 60% of adjusted net income to shareholders by 2018.

Amgen has longer-term opportunities for margin improvement from synergies and cost controls. The company initiated a large-scale "transformation" program in 2013 to focus on efficient allocation of resources. The plan included an approximately 23% reduction in its facilities footprint and a 20% reduction in headcount by the end of 2015, with a goal of generating $1.5 billion of annual savings and a 15-point increase in adjusted operating margin by 2018. So far, the company's adjusted operating margin has increased from 38% in 2013 to 48% in 2015 and 55% in 1Q16. Management believes it is on a path to achieve 52-54% by 2018. In addition, the company's new next-generation bio-manufacturing facility is on track. The facility is expected to increase bulk production capabilities at a quarter of capital costs, 1/3 of operating costs and 2x speed vs. conventional facilities, resulting in an estimated cost reduction of 60%+ per gram of protein.

Competitive threats confront any company and even more so for biotech and pharma companies as their products face patent expirations. Biosimilar products are newer to the marketplace and the regulatory pathway is still evolving, with questions of interchangeability with the branded drug still progressing. Biologics are scientifically more challenging than small molecule generic development, more costly to develop and require high-quality complex manufacturing. Price discounting to date has been substantially less than small molecule generics, but may vary over the longer-term. As such, we look to acquire shares at a reasonable estimate of the company's base business without giving much credit to the pipeline. We believe this provides downside protection for the competitive threats while providing opportunity for upside given the growing pipeline. We took advantage of volatility during the quarter to acquire shares of Amgen common at around a 25% discount to our estimate of NAV.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Top Ranked Articles about Amgen Inc

David Carlson Picks Up Henry Schein, Dumps Amgen Guru releases 2nd-quarter portfolio
David Carlson (Trades, Portfolio), manager of Elfun Trusts, disclosed that he entered one new position and exited another when he released his second-quarter portfolio this week. Read more...
Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
Amgen Announces 2018 Third Quarter Dividend
Amgen Announces Succession Plans For Two Executive Officers
Amgen Announces Webcast of 2018 Second Quarter Financial Results
Amgen And Cedars-Sinai Partner For Improved Healthcare Quality
Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma
AbbVie Authorizes US Sale of Humira Biosimilar Mylan signs license with AbbVie on proposed biosimilar
AbbVie Inc. (NYSE:ABBV) has authorized Mylan NV (NASDAQ:MYL) to market a proposed biosimilar of Humira in the U.S. and other non-European countries. Read more...
Third Avenue Value Fund Sells PNC Financial, Masco Guru’s largest sales of the second quarter.
Third Avenue is a deep value investment firm. During the second quarter it sold shares of the following stocks. Read more...
Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine

Ratios

vs
industry
vs
history
PE Ratio 53.65
AMGN's PE Ratio is ranked lower than
73% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. AMGN: 53.65 )
Ranked among companies with meaningful PE Ratio only.
AMGN' s PE Ratio Range Over the Past 10 Years
Min: 10.4  Med: 16.12 Max: 73.97
Current: 53.65
10.4
73.97
Forward PE Ratio 14.16
AMGN's Forward PE Ratio is ranked higher than
77% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. AMGN: 14.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 53.65
AMGN's PE Ratio without NRI is ranked lower than
73% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. AMGN: 53.65 )
Ranked among companies with meaningful PE Ratio without NRI only.
AMGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.4  Med: 16.12 Max: 73.97
Current: 53.65
10.4
73.97
Price-to-Owner-Earnings 12.90
AMGN's Price-to-Owner-Earnings is ranked higher than
85% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. AMGN: 12.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.72  Med: 12.93 Max: 22.43
Current: 12.9
9.72
22.43
PB Ratio 8.59
AMGN's PB Ratio is ranked lower than
75% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AMGN: 8.59 )
Ranked among companies with meaningful PB Ratio only.
AMGN' s PB Ratio Range Over the Past 10 Years
Min: 1.8  Med: 3.61 Max: 8.62
Current: 8.59
1.8
8.62
PS Ratio 6.01
AMGN's PS Ratio is ranked higher than
67% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 6.01 )
Ranked among companies with meaningful PS Ratio only.
AMGN' s PS Ratio Range Over the Past 10 Years
Min: 3.01  Med: 4.39 Max: 6.55
Current: 6.01
3.01
6.55
Price-to-Free-Cash-Flow 13.20
AMGN's Price-to-Free-Cash-Flow is ranked higher than
81% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. AMGN: 13.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.79  Med: 12.57 Max: 20
Current: 13.2
8.79
20
Price-to-Operating-Cash-Flow 12.43
AMGN's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. AMGN: 12.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.25  Med: 11.44 Max: 17.29
Current: 12.43
7.25
17.29
EV-to-EBIT 11.86
AMGN's EV-to-EBIT is ranked higher than
71% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AMGN: 11.86 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 11.55 Max: 20.7
Current: 11.86
7.4
20.7
EV-to-EBITDA 10.17
AMGN's EV-to-EBITDA is ranked higher than
70% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AMGN: 10.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 9.6 Max: 15.8
Current: 10.17
6.2
15.8
EV-to-Revenue 5.73
AMGN's EV-to-Revenue is ranked higher than
70% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AMGN: 5.73 )
Ranked among companies with meaningful EV-to-Revenue only.
AMGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.7  Med: 4.5 Max: 6.7
Current: 5.73
2.7
6.7
PEG Ratio 3.44
AMGN's PEG Ratio is ranked lower than
63% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. AMGN: 3.44 )
Ranked among companies with meaningful PEG Ratio only.
AMGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.39 Max: 4.36
Current: 3.44
0.64
4.36
Shiller PE Ratio 29.09
AMGN's Shiller PE Ratio is ranked higher than
71% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. AMGN: 29.09 )
Ranked among companies with meaningful Shiller PE Ratio only.
AMGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.3  Med: 26.5 Max: 37.29
Current: 29.09
17.3
37.29
Current Ratio 3.39
AMGN's Current Ratio is ranked lower than
61% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AMGN: 3.39 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.09 Max: 7.44
Current: 3.39
1.31
7.44
Quick Ratio 3.12
AMGN's Quick Ratio is ranked lower than
60% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AMGN: 3.12 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.72 Max: 6.54
Current: 3.12
1.17
6.54
Days Inventory 267.81
AMGN's Days Inventory is ranked lower than
82% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. AMGN: 267.81 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 267.81
219.41
374.86
Days Sales Outstanding 55.16
AMGN's Days Sales Outstanding is ranked higher than
59% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AMGN: 55.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.14 Max: 67.84
Current: 55.16
46.32
67.84
Days Payable 93.23
AMGN's Days Payable is ranked higher than
61% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. AMGN: 93.23 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 80.12  Med: 86.19 Max: 121.28
Current: 93.23
80.12
121.28

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.59
AMGN's Dividend Yield % is ranked higher than
83% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. AMGN: 2.59 )
Ranked among companies with meaningful Dividend Yield % only.
AMGN' s Dividend Yield % Range Over the Past 10 Years
Min: 0.48  Med: 1.76 Max: 2.84
Current: 2.59
0.48
2.84
Dividend Payout Ratio 1.33
AMGN's Dividend Payout Ratio is ranked lower than
93% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. AMGN: 1.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AMGN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.35 Max: 1.71
Current: 1.33
0.14
1.71
3-Year Dividend Growth Rate 23.50
AMGN's 3-Year Dividend Growth Rate is ranked higher than
78% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. AMGN: 23.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AMGN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 63.3
Current: 23.5
0
63.3
Forward Dividend Yield % 2.67
AMGN's Forward Dividend Yield % is ranked higher than
86% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. AMGN: 2.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.49
AMGN's 5-Year Yield-on-Cost % is ranked higher than
96% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. AMGN: 8.49 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AMGN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.58  Med: 5.79 Max: 9.35
Current: 8.49
1.58
9.35
3-Year Average Share Buyback Ratio 1.70
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AMGN: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.1  Med: 0.9 Max: 8.7
Current: 1.7
-10.1
8.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.05
AMGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. AMGN: 1.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.88 Max: 9.49
Current: 1.05
0.61
9.49
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.53
AMGN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
84% of the 38 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. AMGN: 4.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
AMGN' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.83  Med: 1.49 Max: 5.69
Current: 4.53
0.83
5.69
Price-to-Median-PS-Value 1.37
AMGN's Price-to-Median-PS-Value is ranked lower than
69% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AMGN: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.71  Med: 1.37 Max: 5.12
Current: 1.37
0.71
5.12
Price-to-Peter-Lynch-Fair-Value 3.27
AMGN's Price-to-Peter-Lynch-Fair-Value is ranked lower than
80% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. AMGN: 3.27 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.4 Max: 4.12
Current: 3.27
0.58
4.12
Earnings Yield (Greenblatt) % 8.43
AMGN's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AMGN: 8.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.8  Med: 8.65 Max: 13.6
Current: 8.43
4.8
13.6
Forward Rate of Return (Yacktman) % 22.35
AMGN's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. AMGN: 22.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11  Med: 19 Max: 27.2
Current: 22.35
11
27.2

More Statistics

Revenue (TTM) (Mil) $23,188.00
EPS (TTM) $ 3.68
Beta1.69
Volatility15.41%
52-Week Range $163.31 - 201.23
Shares Outstanding (Mil)647.27

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 23,123 22,883 23,191
EBIT (Mil $) 10,651 10,663 10,976
EBITDA (Mil $) 12,366 12,170 12,202
EPS ($) 12.89 13.83 14.95
EPS without NRI ($) 12.89 13.83 14.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.88%
Dividends per Share ($) 4.86 5.02 4.87

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}